ClinicalTrials.gov
ClinicalTrials.gov Menu

Study to Evaluate the Impact of Reactogenicity on Quality of Life (QoL), After Administration of GlaxoSmithKline (GSK) Biologicals' Candidate Herpes Zoster Subunit (HZ/su) Vaccine (GSK1437173A) in Adults ≥ 50 Years of Age

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02979639
Recruitment Status : Completed
First Posted : December 1, 2016
Results First Posted : October 16, 2018
Last Update Posted : October 16, 2018
Sponsor:
Information provided by (Responsible Party):
GlaxoSmithKline

Brief Summary:
The purpose of this study is to evaluate the impact of reactogenicity of GSK Biologicals' HZ/su vaccine on Quality of Life (QoL) in adults ≥ 50 years of age

Condition or disease Intervention/treatment Phase
Herpes Zoster Biological: GSK Biologicals Herpes Zoster subunit (HZ/su) vaccine (GSK 1437173A) Phase 3

Detailed Description:
The study will evaluate the impact of HZ/su vaccination on the QoL, 400 adults ≥ 50 years of age (YOA). Subjects will be asked to respond to a series of SF-36 and EQ-5D questionnaires before and after vaccination following a 2 month schedule. To estimate the impact of reactogenicity on an individual's physical functioning (PF) and QoL, the study will compare subject questionnaire responses made during two periods, i.e., pre-vaccination and post-vaccination. The difference will be considered to be the effect of vaccination and reactogenicity on the PF and QoL. To characterize the study population and determine if frailty may influence reactogenicity and consequently the impact on QoL scores, the subjects' frailty status will be assessed at the first inclusion visit. In addition to the SF-36 and EQ-5D questionnaires, a more complete characterization of the reactogenicity of the vaccine will be made by including a detailed collection of the use of healthcare resources and the occurrence of symptoms through diary card data collection. Impact on days of work loss, both for the subject or for a caregiver, as applicable, will also be assessed.

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 404 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Prevention
Official Title: Study to Evaluate the Impact of Reactogenicity on Quality of Life (QoL), After Administration of GSK Biologicals' Candidate Herpes Zoster Subunit (HZ/su) Vaccine (GSK1437173A) in Adults ≥ 50 Years of Age
Actual Study Start Date : January 16, 2017
Actual Primary Completion Date : April 12, 2017
Actual Study Completion Date : May 24, 2018

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Shingles

Arm Intervention/treatment
Experimental: GSK1437173A Group
Subjects ≥ 50 years of age who will receive two doses of the GSK1437173A vaccine (first dose given at Month 0 and second dose given 2 months later) in this study.
Biological: GSK Biologicals Herpes Zoster subunit (HZ/su) vaccine (GSK 1437173A)
2 doses administered by intramuscular (IM) injection into the deltoid muscle of the non-dominant arm on a 2 month schedule.




Primary Outcome Measures :
  1. Change in the Short Form 36-item-health Survey (SF36) Physical Functionning (PF) From Baseline Score to Mean Score. [ Time Frame: From Baseline at Day -7 to Day 7 after first dose ]
    Descriptive analysis of the mean and standard deviation (SD) of the change from baseline of the SF-36 physical functioning (PF) score pre- and post dose 1 overall. Changes in the score were measured as Baseline versus mean score over the period Day 1 to Day 7 after first vaccination. Baseline for dose 1 is defined as the mean of the assessments at Day -7 and Day 0. The post-vaccination completion of SF-36 questionnaires brought home by the subjects were Days 1 to 6, with Day 7 to be filled in at the site. The SF-36 scale scores are constructed following the summated ratings of the questions and standardized SF-36 scoring algorithm. Scores range from 0 to 100, with a higher score representing a higher level of functioning.


Secondary Outcome Measures :
  1. Change in Mean SF-36 PF Single Item Scores. [ Time Frame: From Baseline at Day -7 to Day 7 after first dose ]

    Descriptive analysis of the change in mean SF-36 PF single item score from baseline. Changes in the score were measured as Baseline versus mean score over the period Day 1 to Day 7 after the first vaccination. Baseline for dose 1 is defined as the mean of the assessments at Day -7 and Day 0.

    The post-vaccination completion of SF-36 questionnaires brought home by the subjects were Days 1 to 6, with Day 7 to be filled in at the site. The SF-36 scale scores are constructed following the summated ratings of the questions and standardized SF-36 scoring algorithm. Scores range from 0 to 100, with a higher score representing a higher level of functioning.

    Among items are vigorous activities (running, lifting heavy objects, participating in strenuous sports), moderate activities (moving a table, pushing a vaccum cleaner, bowling, or playing golf) and others, described in the categories below.


  2. Change in SF-36 Role Physical Scores. [ Time Frame: From Baseline at Day -7 to Day 7 after first dose ]
    Descriptive analysis. SF-36 Role physical scores change will be measured from baseline score. Baseline versus mean score on Day 7 after first vaccination. Baseline for dose 1 is defined as the mean of the assessments at Day -7 and Day 0. The post-vaccination completion of SF-36 questionnaires brought home by the subjects were on Day 1 to Day 6, with Day 7 to be filled in at the site. The SF-36 scale scores are constructed following the summated ratings of the questions and standardized SF-36 scoring algorithm. Scores range from 0 to 100, with a higher score representing a higher level of functioning.

  3. Change in Quality-adjusted Life Year (QALY). [ Time Frame: From Baseline at Day -7 to Day 7 after first dose ]
    Descriptive analysis. QALY estimation is done from baseline score, based on EQ-5D questionnaires. Baseline versus combined score over the period Day 1 to Day 7 after each vaccination. Baseline for dose 1 is defined as the mean of the assessments at Day -7 and Day 0. The post-vaccination completion of EQ-5D questionnaires brought home by the subjects were on Day 1 to Day 6, with Day 7 to be filled in at the site. The EQ-5D is a generic measure of health status that provides a simple description profile based on 5 items: mobility, self-care, usual activities, pain/discomfort and anxiety/depression, which are used to generate the EQ-5D index utility score. The EQ-5D index utility score ranges from 0 (worst health state) to 1 (perfect health state); 1 reflects the best outcome.

  4. Number of Reactogenicity-triggered Medically Attended Visits [ Time Frame: From Day 0 to Day 6 after first dose ]
    Medical attention and health resource utilization triggered by frequency of reactogenicity events. Healthcare resources included staff involved in the following activities: telephone calls, visit to general practitioner, visit to specialist, visit to emergency room and hospitalizations.

  5. Days of Work Loss for Subjects. [ Time Frame: From Day 0 to Day 6 after first dose ]
    Descriptive analysis. Estimation of work loss due to any reaction related to the study vaccine for subjects, expressed in days.

  6. Days of Work Loss for the Non-dedicated Caregivers. [ Time Frame: From Day 0 to Day 6 after first dose ]
    Descriptive analysis. Estimation of work loss of non-dedicated caregivers expressed in days.

  7. Days of Extra Work for Dedicated Caregivers. [ Time Frame: From Day 0 to Day 6 after first dose ]
    Descriptive analysis. Estimation of extra work for non-dedicated caregivers.

  8. Number of Subjects With Any and Grade 3 Solicited Local Symptoms. [ Time Frame: During a 7-day follow-up period (Day 0 to Day 6) after first dose. ]
    Assessed solicited local symptoms were pain, redness and swelling. Any = occurrence of the symptom regardless of intensity grade. Grade 3 pain = pain that prevented normal activity. Grade 3 redness/swelling = redness/swelling spreading beyond 100 millimeters (mm) of injection site.

  9. Number of Days With Local Symptoms [ Time Frame: During a 7-day follow-up period (Day 0 to Day 6) after first dose. ]
    Assessed solicited local symptoms were pain, redness and swelling.

  10. Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms. [ Time Frame: During a 7-day follow-up period (Day 0 to Day 6) after first dose. ]
    Assessed solicited general symptoms were fatigue, gastrointestinal symptoms, headache, myalgia, shivering and temperature [defined as oral, axillary or tympanic temperature equal to or above (≥)37.5 degrees Celsius (°C), or rectal temperature ≥ 38.0°C]. Any = occurrence of the symptom regardless of intensity grade. Grade 3 symptom = symptom that prevented normal everyday activities. Grade 3 temperature = > 39.0 °C. Related = symptom assessed by the investigator as related to the vaccination.

  11. Number of Days With General Symptoms [ Time Frame: During a 7-day follow-up period (Day 0 to Day 6) after first dose. ]
    Assessed solicited general symptoms were fatigue, gastrointestinal symptoms, headache, myalgia, shivering and temperature [defined as oral, axillary or tympanic temperature equal to or above (≥)37.5 degrees Celsius (°C), or rectal temperature ≥ 38.0°C].

  12. Number of Subjects With Serious Adverse Events (SAEs). [ Time Frame: From Day 0 to Day 7 after first dose ]
    SAEs assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization, result in disability/incapacity or is a congenital anomaly/birth defect in the offspring of a study subject.

  13. Change in Mean SF-36 PF Scale Scores. [ Time Frame: From Day -7 to first dose until Day 7 after second dose (equivalent to study Days -7 to 67) ]

    Descriptive analysis of the change in mean SF-36 PF scale score from baseline. Changes in the score were measured as Baseline versus mean score over the period Day 1 to Day 7 after second vaccination.

    For dose 2 baseline is defined as the mean of the three assessments at Day -7, Day 0 and Day 60 (Day 0 for dose 2).

    The post-vaccination completion of SF-36 questionnaires brought home by the subjects were on Day 1 to Day 6, with Day 7 to be filled in at the site. The SF-36 scale scores are constructed following the summated ratings of the questions and standardized SF-36 scoring algorithm. Scores range from 0 to 100, with a higher score representing a higher level of functioning.


  14. Change in Mean SF-36 PF Single Item Scores. [ Time Frame: From Day -7 to first dose until Day 7 after second dose (equivalent to study Days -7 to 67) ]

    Descriptive analysis of the change in mean SF-36 PF single item score from baseline. Baseline versus mean score over the period Day 1 to Day 7 after each vaccination. For dose 2 baseline is defined as the mean of the three assessments at Day -7, Day 0 and Day 60 (equivalent to Day 0 for dose 2) The post-vaccination completion of SF-36 questionnaires brought home by the subjects were on Day 1 to Day 6, with Day 7 to be filled in at the site. The SF-36 scale scores are constructed following the summated ratings of the questions and standardized SF-36 scoring algorithm. Scores range from 0 to 100, with a higher score representing a higher level of functioning.

    Among items are vigorous activities (running, lifting heavy objects, participating in strenuous sports), moderate activities (moving a table, pushing a vaccum cleaner, bowling, or playing golf) and others, described in the categories below.


  15. Change in SF-36 Role Physical Scores. [ Time Frame: From Day -7 to first dose until Day 7 after second dose (equivalent to study Days -7 to 67) ]
    Descriptive analysis. SF-36 Role physical scores change was measured from baseline score. Changes in the score were measured as Baseline versus Day 7 score after the second vaccination. For dose 2 baseline is defined as the mean of the three assessments at Day -7, Day 0 and Day 60 (equivalent to Day 0 for dose 2) The post-vaccination completion of SF-36 questionnaires brought home by the subjects were on Day 1 to Day 6, with Day 7 to be filled in at the site. The SF-36 scale scores are constructed following the summated ratings of the questions and standardized SF-36 scoring algorithm. Scores range from 0 to 100, with a higher score representing a higher level of functioning.

  16. Change in QALY [ Time Frame: From Day -7 to first dose until Day 7 after second dose (equivalent to study Days -7 to 67) ]
    Descriptive analysis. QALY estimation is done from baseline score, based on EQ-5D questionnaires. Baseline versus combined score over the period Day 1 to Day 7 after each vaccination. For dose 2 baseline is defined as the mean of the three assessments at Day -7, Day 0 and Day 60 (equivalent to Day 0 for dose 2) The post-vaccination completion of SF-36 and EQ-5D questionnaires brought home by the subjects were on Day 1 to Day 6, with Day 7 to be filled in at the site. The EQ-5D is a generic measure of health status that provides a simple description profile based on 5 items: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. The 5 items are combined to generate health profiles (e.g. 1-no problem/no symptom) and profiles are subsequently converted to a continuous single index utility score (higher scores represent a better quality of life).

  17. Number of Subjects With Any, Grade 3 and Related Unsolicited Adverse Events (AEs). [ Time Frame: During a 30-day follow-up period (Day 0 to Day 29) after first dose. ]
    An unsolicited AE covers any untoward medical occurrence in a clinical investigation subject temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product and reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms. Any was defined as the occurrence of any unsolicited AE regardless of intensity grade or relation to vaccination. Grade 3 AE = an AE which prevented normal, everyday activities. Related = AE assessed by the investigator as related to the vaccination.

  18. Number of Reactogenicity-triggered Medically Attended Visits [ Time Frame: From Day 0 to Day 6 after second dose ]
    Medical attention and health resource utilization triggered by frequency of reactogenicity events. Healthcare resources included staff involved in the following activities: telephone calls, visit to general practitioner, visit to specialist, visit to emergency room and hospitalizations.

  19. Days of Work Loss for Subjects. [ Time Frame: From Day 0 to Day 6 after second dose ]
    Descriptive analysis. Estimation of work loss due to any reaction related to the study vaccine for subjects, expressed in days.

  20. Days of Work Loss for the Non-dedicated Caregivers. [ Time Frame: From Day 0 to Day 6 after second dose ]
    Descriptive analysis. Estimation of work loss due to any reaction related to the study vaccine for non-dedicated caregivers, expressed in days.

  21. Days of Extra Work for Dedicated Caregivers. [ Time Frame: From Day 0 to Day 6 after second dose ]
    Descriptive analysis. Estimation of extra work for non-dedicated caregivers, expressed in days.

  22. Number of Subjects With Any and Grade 3 Solicited Local Symptoms [ Time Frame: During a 7-day follow-up period (Day 0 to Day 6) after second dose. ]
    Assessed solicited local symptoms were pain, redness and swelling. Any = occurrence of the symptom regardless of intensity grade. Grade 3 pain = significant pain at rest, that prevented normal activity. Grade 3 redness/swelling = redness/swelling spreading beyond 100 millimeters (mm) of injection site.

  23. Number of Days With Local Symptoms [ Time Frame: During a 7-day follow-up period (Day 0 to Day 6) after second dose. ]
    Assessed solicited local symptoms were pain, redness and swelling.

  24. Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms. [ Time Frame: During a 7-day follow-up period (Day 0 to Day 6) after second dose. ]
    Assessed solicited general symptoms were fatigue, gastrointestinal symptoms, headache, myalgia, shivering and temperature [defined as axillary temperature equal to or above 37.5 °C]. Any = occurrence of the symptom regardless of intensity grade. Grade 3 symptom = symptom that prevented normal activity. Grade 3 temperature = temperature> 39.0 °C. Related = symptom assessed by the investigator as related to the vaccination.

  25. Number of Days With Solicited General Symptoms [ Time Frame: During a 7-day follow-up period (Day 0 to Day 6) after second dose. ]
    Assessed solicited general symptoms were fatigue, gastrointestinal symptoms, headache, myalgia, shivering and temperature [defined as oral, axillary or tympanic temperature equal to or above (≥)37.5 degrees Celsius (°C), or rectal temperature ≥ 38.0°C].

  26. Number of Subjects With Any, Grade 3 and Related Unsolicited Adverse Events (AEs). [ Time Frame: During a 30-day follow-up period (Day 0 to Day 29) after second dose. ]
    An unsolicited AE covers any untoward medical occurrence in a clinical investigation subject temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product and reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms. Any was defined as the occurrence of any unsolicited AE regardless of intensity grade or relation to vaccination. Grade 3 AE = an AE which prevented normal, everyday activities. Related = AE assessed by the investigator as related to the vaccination.

  27. Number of Subjects With SAEs [ Time Frame: From Day 0 to study end at Month 14 ]
    SAEs assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization, result in disability/incapacity or is a congenital anomaly/birth defect in the offspring of a study subject.

  28. Number of Subjects Reporting Any Potential Immune-mediated Diseases (pIMDs) [ Time Frame: From Day 0 to study end at Month 14 ]
    pIMDs are a subset of AEs that include autoimmune diseases and other inflammatory and/or neurologic disorders of interest which may or may not have an autoimmune aetiology.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   50 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Subjects who, in the opinion of the investigator, can and will comply with the requirements of the protocol (e.g., completion of the questionnaires and diary cards).
  • Written informed consent obtained from the subject prior to performance of any study specific procedure.
  • A male or female aged ≥ 50 YOA at the time of consent.
  • Female subjects of non-childbearing potential may be enrolled in the study.

    • For this study population, non-childbearing potential is defined as current tubal ligation, hysterectomy, ovariectomy or post-menopause.
  • Female subjects of childbearing potential may be enrolled in the study, if the subject:

    • has practiced adequate contraception for 30 days prior to vaccination, and
    • has a negative pregnancy test on the day of vaccination, and
    • has agreed to continue adequate contraception during the entire treatment period and for 2 months after completion of the vaccination series.

Exclusion Criteria:

  • Any condition which, in the judgment of the investigator, would make intramuscular (IM) injection unsafe.
  • Use or planned use of any investigational or non-registered product (drug or vaccine) other than the study vaccine or current participation or planned concurrent participation in another clinical study, in which the subject has been or will be exposed to an investigational or a non-investigational product (pharmaceutical product or device) during the period starting 30 days before the first dose of study vaccine and the study end.
  • Use or anticipated use of immunosuppressants or other immune-modifying drugs during the period starting 180 days prior to study start and during the whole study period. This includes chronic administration of corticosteroids (> 14 consecutive days of prednisone at a dose of ≥ 20 mg/day [or equivalent]), long-acting immune-modifying agents (e.g., infliximab) or immunosuppressive/cytotoxic therapy (e.g., medications used during cancer chemotherapy, organ transplantation or to treat autoimmune disorders). Inhaled, topical and intra-articular corticosteroids are allowed.
  • Any confirmed or suspected immunosuppressive or immunodeficient condition resulting from disease (e.g., malignancy, human immunodeficiency virus [HIV] infection) or immunosuppressive/cytotoxic therapy (e.g., medications used during cancer chemotherapy, organ transplantation or to treat autoimmune disorders).
  • Administration of immunoglobulins and/or any blood products in the period starting 90 days preceding the first dose of study vaccine or planned administration during the study period.
  • Administration or planned administration of a live vaccine in the period starting 30 days before the first dose of study vaccine and ending 30 days after the last dose of study vaccine, or, administration or planned administration of a non-replicating vaccine in the period starting 15 days prior to and ending 14 days after either dose of study vaccine.
  • Previous or planned administration of a vaccine against HZ (including an investigational or non-registered vaccine) other than the study vaccine, during the entire study period.
  • History of HZ.
  • History of any reaction or hypersensitivity likely to be exacerbated by any component of the vaccine.
  • Female planning to become pregnant or planning to discontinue contraceptive precautions.
  • Pregnant or lactating female.
  • Significant underlying illness requiring medications that might confound the evaluation of general/ local AEs, or in the opinion of the investigator, would be expected to prevent completion of the study.
  • Any other condition that, in the opinion of the investigator, might interfere with the evaluations required by the study.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02979639


Locations
United States, California
GSK Investigational Site
Oakland, California, United States, 94612
United States, Colorado
GSK Investigational Site
Aurora, Colorado, United States, 80045
GSK Investigational Site
Colorado Springs, Colorado, United States, 80906
GSK Investigational Site
Colorado Springs, Colorado, United States, 80922
United States, Idaho
GSK Investigational Site
Meridian, Idaho, United States, 83646
United States, Missouri
GSK Investigational Site
Kansas City, Missouri, United States, 64114
United States, North Carolina
GSK Investigational Site
Durham, North Carolina, United States, 27705
United States, Oregon
GSK Investigational Site
Corvallis, Oregon, United States, 97330
United States, Pennsylvania
GSK Investigational Site
Uniontown, Pennsylvania, United States, 15401
United States, South Carolina
GSK Investigational Site
Spartanburg, South Carolina, United States, 29303
United States, Virginia
GSK Investigational Site
Norfolk, Virginia, United States, 23507
Sponsors and Collaborators
GlaxoSmithKline
Investigators
Study Director: GSK Clinical Trials GlaxoSmithKline
  Study Documents (Full-Text)

Documents provided by GlaxoSmithKline:
Statistical Analysis Plan  [PDF] May 30, 2017
Study Protocol  [PDF] November 16, 2016


Responsible Party: GlaxoSmithKline
ClinicalTrials.gov Identifier: NCT02979639     History of Changes
Other Study ID Numbers: 204928
First Posted: December 1, 2016    Key Record Dates
Results First Posted: October 16, 2018
Last Update Posted: October 16, 2018
Last Verified: September 2018

Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No

Keywords provided by GlaxoSmithKline:
Herpes Zoster
Reactogenicity
Quality of life
Shingles

Additional relevant MeSH terms:
Herpes Zoster
Herpesviridae Infections
DNA Virus Infections
Virus Diseases
Vaccines
Immunologic Factors
Physiological Effects of Drugs